Isembyld
US · Intravenous infusionSpinal muscular atrophy in patients aged 2 years and older receiving an SMN2-targeted treatment
ADJACENT BIOLOGICS
Apitegromab-mstn
An adjacent muscle-pathway comparator. Apitegromab is an IgG4 monoclonal antibody, not a peptide or wellness product.
FDA STATUS
FDA approved as Isembyld on 11 September 2026 for spinal muscular atrophy in patients aged 2 years and older who are receiving an SMN2-targeted treatment
MHRA / UK LICENCE
The US approval does not establish UK marketing authorisation. UK status requires separate MHRA verification
PRIVATE LAWFUL USE CONTEXT
This is a protein biologic authorised for a defined US specialist indication. It is not a peptide or wellness product
EVIDENCE MATURITY
FDA authorised protein biologic for a defined spinal muscular atrophy indication and population
PROFESSIONAL RELEVANCE
Use as a comparator for specialist muscle-pathway innovation while keeping its product class, US indication and UK status boundaries explicit.
Product, formulation and indication
Status history
Isembyld approval of 11 September 2026 added as a separate adjacent biologic comparator.
FDA approved adjacent biologic targeting muscle loss in spinal muscular atrophy
Future material changes will be appended with their previous status and source; they will not be silently overwritten.
Verify this record
Source labels identify what each link can prove. Sponsor material is used for time sensitive development claims only.
- PRIMARYFDA · Isembyld approval announcement, 11 September 2026
- PRIMARYFDA · GINAS apitegromab substance record
- PRIMARYFDA · 2026 novel drug approvals register
- PRIMARYMHRA · product information verification route
- PRIMARYNICE · guidance search verification route
- MARKET SIGNALMarket exposure classification method